ADAM17 and hepatocellular carcinoma: These findings establish a correlation between ADAM17 and Notch signaling, which has been previously reported in various diseases, including prostate tumors, non–small cell lung carcinoma, hepatocellular carcinoma, and diabetic nephropathy (55–57).